UNDERSTANDING HEMATOLOGIC ARs
WITH ABRAXANE + GEMCITABINE

UNDERSTANDING HEMATOLOGIC ARs WITH ABRAXANE + GEMCITABINE

Percentage of patients who experience Neutropenia in the ABRAXANE Phase III MPAC Study Percentage of patients who experience Thrombocytopenia in the ABRAXANE Phase III MPAC Study Percentage of patients who experience Thrombocytopenia in the ABRAXANE Phase III MPAC Study
26% of ABRAXANE + gemcitabine patients received granulocyte colony stimulating factor (G-CSF).
  • Dose Modifications for Hematologic ARs

    APPROPRIATE DOSE MODIFICATIONS FOR HEMATOLOGIC ARs

    Monitor for myelotoxicity by performing complete blood cell counts frequently, including prior to dosing on Days 1, 8, and 15
    metastatic pancreatic cancer day 1
    Assess whether to begin or delay treatment cycle (based on CBC prior to dosing on Day 1)
    • Patients must have ANC ≥1500 cells/mm3 and platelet counts ≥100,000 cells/mm3 to initiate a cycle
    • If counts are not at these levels, delay the start of the cycle until recovery
    The recommended starting dose of ABRAXANE is 125 mg/m2
    metastatic pancreatic cancer day 1
    Assess whether to begin or delay treatment cycle (based on CBC prior to dosing on Day 1)
    • Patients must have ANC ≥1500 cells/mm3 and platelet counts ≥100,000 cells/mm3 to initiate a cycle
    • If counts are not at these levels, delay the start of the cycle until recovery
    The recommended starting dose of ABRAXANE is 125 mg/m2
    Adjust treatment as necessary within the cycle based on ANC and platelet counts
    (determined via CBC prior to dosing on Days 8 and 15)
    Adjust treatment as necessary within the cycle based on ANC and platelet counts
    (determined via CBC prior to dosing on Days 8 and 15)
    metastatic pancreatic cancer day 8
    metastatic pancreatic cancer day 8
    Hematologic ARs dose Modifications Day 8 Hematologic ARs dose Modifications Day 8
    Dose Modification for Hematologic ARs at the start of each cycle for Metastatic Pancreatic cancer- Day 8 Dose Modification for Hematologic ARs at the start of each cycle for Metastatic Pancreatic cancer- Day 8
    Dose Modification for Hematologic ARs at the start of each cycle for Metastatic Pancreatic cancer- Day 8 Dose Modification for Hematologic ARs at the start of each cycle for Metastatic Pancreatic cancer- Day 8
    metastatic pancreatic cancer day 15 metastatic pancreatic cancer day 15
    Treatment adjustments at Day 15 depend upon action taken at Day 8
    SELECT ACTION TAKEN ON DAY 8 ABOVE TO SEE APPROPRIATE DOSE MODIFICATIONS FOR DAY 15
    metastatic pancreatic cancer day 15 metastatic pancreatic cancer day 15
    Dose Modification for Hematologic ARs at the start of each cycle for Metastatic Pancreatic cancer- Day 15 Dose Modification for Hematologic ARs at the start of each cycle for Metastatic Pancreatic cancer- Day 15
    Dose Modification for Henatologic ARs at the start of each cycle for Metastatic Pancreatic cancer- Day 15 Dose Modification for Henatologic ARs at the start of each cycle for Metastatic Pancreatic cancer- Day 15
    Dose Modification for Hematologic ARs at the start of each cycle for Metastatic Pancreatic cancer- Day 15 Dose Modification for Hematologic ARs at the start of each cycle for Metastatic Pancreatic cancer- Day 15
    metastatic pancreatic cancer day 15 metastatic pancreatic cancer day 15
    metastatic pancreatic cancer maintain day 8 dose metastatic pancreatic cancer maintain day 8 dose
    Dose Modification for Hematologic ARs at the start of each cycle for Metastatic Pancreatic cancer- Day 15 Dose Modification for Hematologic ARs at the start of each cycle for Metastatic Pancreatic cancer- Day 15
    Dose Modification for Hematologic ARs at the start of each cycle for Metastatic Pancreatic cancer- Day 15 Dose Modification for Hematologic ARs at the start of each cycle for Metastatic Pancreatic cancer- Day 15
    metastatic pancreatic cancer day 15 metastatic pancreatic cancer day 15
    Dose Modification for Hematologic ARs at the start of each cycle for Metastatic Pancreatic cancer- Day 15 Dose Modification for Hematologic ARs at the start of each cycle for Metastatic Pancreatic cancer- Day 15
    Dose Modification for Hematologic ARs at the start of each cycle for Metastatic Pancreatic cancer- Day 15 Dose Modification for Hematologic ARs at the start of each cycle for Metastatic Pancreatic cancer- Day 15
    Dose Modification for Hematlologic ARs at the start of each cycle for Metastatic Pancreatic cancer- Day 15 Dose Modification for Hematlologic ARs at the start of each cycle for Metastatic Pancreatic cancer- Day 15
    If Grade 3 or 4 febrile neutropenia occurs, withhold ABRAXANE and gemcitabine until fever resolves and ANC ≥1500; resume at next lower dose level.
    CLOSE THE TAB
  • Dose Level Reductions

    DOSE LEVEL REDUCTIONS

    Dose level reductions for MPAC patients Dose level reductions for MPAC patients
    CLOSE THE TAB
YOU ARE NOW LEAVING www.abraxanepro.com
Additional Information for Readers Provided by Celgene Corporation

The clinical trial described in this article served as the
basis for the approval for ABRXANE for Injectable Suspension.
The analyses contained in the article may differ from those in the package insert for ABRAXANE.

Please see Important Safety Information and Prescribing Information, including Boxed WARNING.

Click “OK” to proceed or “CANCEL” to return to
www.abraxanepro.com

OK
CANCEL